WO1995011035A1 - Preparation cosmetique a action antivirale pour une utilisation topique - Google Patents

Preparation cosmetique a action antivirale pour une utilisation topique Download PDF

Info

Publication number
WO1995011035A1
WO1995011035A1 PCT/EP1994/003445 EP9403445W WO9511035A1 WO 1995011035 A1 WO1995011035 A1 WO 1995011035A1 EP 9403445 W EP9403445 W EP 9403445W WO 9511035 A1 WO9511035 A1 WO 9511035A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
preparation according
weight
john
extract
Prior art date
Application number
PCT/EP1994/003445
Other languages
German (de)
English (en)
Inventor
Richard HANSMANN
Original Assignee
Beni-Med Natürliche Heilmittel Gmbh & Co. Vertriebs Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beni-Med Natürliche Heilmittel Gmbh & Co. Vertriebs Kg filed Critical Beni-Med Natürliche Heilmittel Gmbh & Co. Vertriebs Kg
Priority to DE9421714U priority Critical patent/DE9421714U1/de
Publication of WO1995011035A1 publication Critical patent/WO1995011035A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips

Definitions

  • the present invention relates to preparations, for example cosmetic or pharmaceutical preparations, with antiviral activity for topical use.
  • Such skin care products should, for example, promote blood circulation in the skin, strengthen the connective tissue and renew the cells, offer protection against the harmful effects of UV radiation, influence the moisture content of the skin and be healing in the case of inflammatory diseases.
  • Ointments contain lanolin as the basis. If ointments are watery, they are called creams, they contain solid components, as pastes.
  • Solutions are offered as a further dosage form. These usually contain water or alcohol as a solvent. Not by adding water
  • miscible oils give emulsions that usually also contain an emulsion enhancer. Suspensions are obtained by adding insoluble solid components. It is also known that lipsticks mostly consist of wax and oils.
  • Liquid extract is an extract of the medicinal plant in a suitable solvent. If the liquid extract is concentrated to an oily consistency, if a spissum extract is obtained, the solvent is completely removed, a dry extract. Methods for extracting medicinal plants are described in the German Medicinal Products Code.
  • St. John's wort When used externally, St. John's wort is used because of its wound healing properties. It develops a particularly with rough and sensitive skin beneficial effect. The essential regeneration ability of infected tissue with a poor tendency to heal is attributed to the essential oil of St. John's wort.
  • DE-OS 24 06 452 describes an ointment for the treatment of burns and a process for the production thereof.
  • this ointment contains St. John's wort extract.
  • St. John's wort is also used as a mild psychopharmaceutical to treat mild to moderate depression.
  • the advantages are the good tolerability of the drug with only minor side effects and the increased acceptance among doctors and patients due to its natural origin.
  • the object of the invention is therefore to provide preparations, for example cosmetic or pharmaceutical preparations with antiviral activity for topical use, which do not have these disadvantages, have a good antiviral activity, are nourishing and enable a high concentration of the active ingredient at the site of the diseased tissue. It has now been found that this object is achieved by preparations, for example cosmetic or pharmaceutical preparations with antiviral activity for topical use, which are characterized in that they contain St. John's wort extract as an antiviral active ingredient, preferably against herpes viruses.
  • St. John's wort extract By means of the use of St. John's wort extract according to the invention, it is possible, using natural active ingredients, to obtain cosmetic or pharmaceutical preparations which have a high antiviral activity, in particular against HSV-1 and HSV-2 viruses.
  • St. John's wort extract is understood to be a St. John's wort liquid extract, a spissum extract or a dry extract, each of natural origin, preparation in accordance with the German pharmaceutical code.
  • the dry extract based on the preparation, is present in the preparation in amounts of 2 to 30% by weight, preferably 5 to 25% by weight, in particular 20% by weight.
  • the spissum extract based on the preparation, is present in amounts of 2 to 15% by weight, preferably 2 to 10% by weight, in particular 5% by weight, based on the preparation. If liquid is used, it is contained in amounts of 5 to 60% by weight, preferably 10 to 50% by weight, in particular 40% by weight, based on the preparation.
  • Hypericin and pseudohypericin are contained in the St. John's wort extract in quantities of 0.02 to 1.2% by weight, preferably 0.5% by weight.
  • the total hypericin content is determined as dianthrone in accordance with the German pharmaceutical code and calculated as hypericin.
  • a preferred embodiment of the preparation according to the invention contains, as an additive, one or more solubilizing substances which improve the action of the St. John's wort extract or its essential ingredients in amounts of 0.5 to 2% by weight, in particular 1% by weight, based on the preparation.
  • ethoxylated sorbitan fatty acid esters such as, for example, polyethoxysorbitan laurate, polyethoxysorbitan palate, polyethoxysorbitan stearate, polyethoxysobitan tristearate, polyethoxysorbitan trioleate.
  • a preferred such fatty acid ester is the product commercially available under the name TWEEN 80 (ICI), which increases the effectiveness of hypericin and pseudohypericin many times over.
  • the preparation according to the invention contains, as an additive, a solubilizing substance with a local anesthetic effect, in quantities of 1 to 3% by weight, in particular 2% by weight, based on the Preparation.
  • a solubilizing substance with a local anesthetic effect in quantities of 1 to 3% by weight, in particular 2% by weight, based on the Preparation.
  • Such an additive is particularly pain-relieving with regard to the painful individual vesicles, vesicle groups and inflammations that are usually associated with herpes.
  • solubilizing substance with a local anesthetic effect special mention should be made of fatty alcohol polyglycol ether.
  • a suitable such substance is the product commercially available under the name Dehydol KE 2567 (CTFA name: Laureth-6).
  • the preparation according to the invention contains an anti-inflammatory agent, in quantities of 0.05 to 0.1% by weight, in particular 0.07% by weight, based on the preparation.
  • a suitable anti-inflammatory agent is ⁇ -bisabolol obtained from chamomile or the buds of some poplar species.
  • a preparation in the form of ointment, cream or paste based on conventional ointment, cream or paste components can be used as the dosage form. This preparation is particularly favorable for large-scale use.
  • a further form of the preparation can be a spray, preferably an intimate spray, especially against herpes diseases of the genital area.
  • the preparation can also be carried out in solution, emulsion or paste.
  • the preparation is carried out as a lipstick on the basis of the usual
  • Lipstick ingredients The lipstick makes it possible to hit the desired site of action particularly precisely, even at locations other than lips
  • cream is prepared in a known manner from the mixture of the following components:
  • Cetyl alcohol 1.8 g medium fat triglycerides 2.25 g white petroleum jelly 1.65 g
  • An ointment according to the invention is produced in a known manner from a mixture of the following components:
  • a solution for vaginal use which can also be used as a pump spray, is produced according to the invention from a mixture of the following components:
  • Macrogol stearate 400 0.15 g medium fat triglycerides 1.25 g
  • the St. John's wort extract is solubilized in a suitable manner by rubbing with the abovementioned substances in such a way that a suspension free of suspended matter is formed which is suitable as a pump spray liquid for vaginal use.
  • Lipsticks are made in the known way from a mixture of the following substances:
  • Titanium (IV) oxide 2.0 g

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à des préparations, par exemple des préparations cosmétiques ou pharmaceutiques à action antivirale pour une utilisation topique. L'extrait de millepertuis est employé comme substance active et le produit peut être administré sous forme d'onguent, de crème, d'aérosol et de crayon à lèvres. Les préparations ont une action antivirale et conviennent en particulier pour le traitement des herpès.
PCT/EP1994/003445 1993-10-20 1994-10-20 Preparation cosmetique a action antivirale pour une utilisation topique WO1995011035A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE9421714U DE9421714U1 (de) 1993-10-20 1994-10-20 Kosmetische Zubereitung mit antiviraler Wirkung zur topischen Anwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE9316320U DE9316320U1 (de) 1993-10-20 1993-10-20 Kosmetische Zubereitung in Form von Lippenstiften mit antiviraler Wirkung
DEG9316320.7U 1993-10-20

Publications (1)

Publication Number Publication Date
WO1995011035A1 true WO1995011035A1 (fr) 1995-04-27

Family

ID=6899888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/003445 WO1995011035A1 (fr) 1993-10-20 1994-10-20 Preparation cosmetique a action antivirale pour une utilisation topique

Country Status (2)

Country Link
DE (1) DE9316320U1 (fr)
WO (1) WO1995011035A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030660A2 (fr) * 1998-11-25 2000-06-02 Universitätsklinikum Freiburg Hyperforine s'utilisant comme cytostatique et pommade ou creme a base d'hyperforine comme forme galenique d'application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012207989A1 (de) * 2012-05-14 2013-11-14 Beiersdorf Ag Aromatisierte Lippenbutter

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256452A2 (fr) * 1986-08-08 1988-02-24 Yeda Research And Development Company Limited Compositions pharmaceutiques antivirales contenant de l'hypericine ou du pseudohypericine
US4898891A (en) * 1987-08-07 1990-02-06 Yeda Research And Development Company Ltd. Antiviral compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924774T2 (de) * 1988-07-07 1996-05-02 Univ Pennsylvania Modulation von virus-wirtszell-wechselwirkungen unter verwendung von cyclischen oligosacchariden.
DE3841562A1 (de) * 1988-12-09 1990-06-13 Roth Carl Gmbh & Co Arzneimittel und seine verwendung
DE3912433A1 (de) * 1989-04-15 1990-10-18 Gustav Dr Klein Verfahren zur galenischen zubereitung von hypericin und hypericin-derivaten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256452A2 (fr) * 1986-08-08 1988-02-24 Yeda Research And Development Company Limited Compositions pharmaceutiques antivirales contenant de l'hypericine ou du pseudohypericine
US4898891A (en) * 1987-08-07 1990-02-06 Yeda Research And Development Company Ltd. Antiviral compositions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030660A2 (fr) * 1998-11-25 2000-06-02 Universitätsklinikum Freiburg Hyperforine s'utilisant comme cytostatique et pommade ou creme a base d'hyperforine comme forme galenique d'application
WO2000030660A3 (fr) * 1998-11-25 2001-03-01 Universitaetsklinikum Freiburg Hyperforine s'utilisant comme cytostatique et pommade ou creme a base d'hyperforine comme forme galenique d'application
EP1275382A2 (fr) * 1998-11-25 2003-01-15 Universitätsklinikum Freiburg Hyperforine s'utilisant comme cytostatique et pommade ou crème à base d'hyperforine comme forme galénique d'application
EP1275382A3 (fr) * 1998-11-25 2003-02-12 Universitätsklinikum Freiburg Hyperforine s'utilisant comme cytostatique et pommade ou crème à base d'hyperforine comme forme galénique d'application
US7179495B1 (en) 1998-11-25 2007-02-20 Universitaetsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form

Also Published As

Publication number Publication date
DE9316320U1 (de) 1994-01-20

Similar Documents

Publication Publication Date Title
DE3880769T2 (de) Topische Behandlung von Störungen kranker Haut.
DE60313597T2 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
EP0847279B1 (fr) Compositions cosmetiques et/ou pharmaceutiques antiprurigineuses contenant un ou plusieurs anesthesiques locaux legers et un ou plusieurs astringents
DE3780009T2 (de) Antioxidationszusammensetzungen und verfahren zu ihrer verwendung.
DE10228837B4 (de) Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
DE3032462A1 (de) Praeparate zur anwendung an oder in geweben und/oder fluessigkeiten des menschlichen oder tierischen koerpers
DE3413052A1 (de) Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen
DE3836971C1 (fr)
DE2802924A1 (de) Heilmittel zur behandlung von akne
DE60004786T2 (de) Verfahren und zusammensetzung zur behandlung von akne
DE2131441B2 (de) Hautbleichmittel
DE69727239T2 (de) Bis zu 1% enthaltendes flavonoid extrakt von gingko biloba mit ceramiden für die orale hygiene und diese enthaltende zusammensetzungen
EP1275382A2 (fr) Hyperforine s'utilisant comme cytostatique et pommade ou crème à base d'hyperforine comme forme galénique d'application
EP1399173A2 (fr) Preparation pharmaceutique
WO1995011035A1 (fr) Preparation cosmetique a action antivirale pour une utilisation topique
DE1667890C3 (de) Dermatologische und kosmetische äußerlich anzuwendende Mittel zur Be handlung von Hautkollagenosen
DE69433923T2 (de) Salbe enthaltend mometason-furoat und salicylsäure zur topischen behandlung von psoriasis
DE19821971C2 (de) Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis
EP1131101B1 (fr) Preparation de khelline et son utilisation pour des traitements a action locale
DE9421714U1 (de) Kosmetische Zubereitung mit antiviraler Wirkung zur topischen Anwendung
DE4010042A1 (de) Verwendung von efeu zur topischen behandlung vermehrter schuppenbildung der behaarten und unbehaarten haut sowie der psoriasis
DE2720420A1 (de) Wirkstoffkombination gegen sonnenerythem und diese enthaltendes arzneimittel
DE1922192C2 (de) Zusammensetzungen zur Behandlung von trophischen Störungen der Haut und Verfahren zu ihrer Herstellung
DE4221537A1 (de) Hamamelis-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung als Arzneimittel
DE10118382A1 (de) Hautfaltenbehandlungsmittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase